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Abstract
Objective: Though cigarette smoking (CS) is a well-known risk factor for
ischemic stroke (IS), there is no data on how CS affects the blood transcrip-
tome in IS patients. Methods: We recruited IS-current smokers (IS-SM), IS-
never smokers (IS-NSM), control-smokers (C-SM), and control-never smokers
(C-NSM). mRNA expression was assessed on HTA-2.0 microarrays and
unique as well as commonly expressed genes identified for IS-SM versus IS-
NSM and C-SM versus C-NSM. Results: One hundred and fifty-eight genes
were differentially expressed in IS-SM versus IS-NSM; 100 genes were differen-
tially expressed in C-SM versus C-NSM; and 10 genes were common to both
IS-SM and C-SM (P < 0.01; |fold change| ≥ 1.2). Functional pathway analysis
showed the 158 IS-SM-regulated genes were associated with T-cell receptor,
cytokine–cytokine receptor, chemokine, adipocytokine, tight junction, Jak-
STAT, ubiquitin-mediated proteolysis, and adherens junction signaling. IS-SM
showed more altered genes and functional networks than C-SM. Interpreta-
tion: We propose some of the 10 genes that are elevated in both IS-SM and
C-SM (GRP15, LRRN3, CLDND1, ICOS, GCNT4, VPS13A, DAP3, SNORA54,
HIST1H1D, and SCARNA6) might contribute to increased risk of stroke in
current smokers, and some genes expressed by blood leukocytes and platelets
after stroke in smokers might contribute to worse stroke outcomes that occur
in smokers.
Introduction
Cigarette smoking (CS) is a significant, modifiable risk
factor for ischemic stroke (IS).1–10 CS accounts for
roughly 15% of all stroke death and has a dose-response
relationship in older age subjects.11 Smoking cessation
not only rapidly reduces the risk of primary stroke, with
the risk almost disappearing within 4 years of smoking
cessation, but also improves outcomes of recurrent
IS.4,7,10,11
Smoking has a variety of detrimental effects on the cere-
brovascular and cardiovascular systems by promoting
endothelial dysfunction, systemic inflammation, high levels
of low-density lipoprotein cholesterol, atherosclerosis,
platelet aggregation, and clot formation.9 Thus, smoking
increases the rates of stroke as well as myocardial infarc-
tion. Herein, we hypothesize that CS induces gene expres-
sion changes, especially in inflammation-related and
platelet aggregation-related genes, resulting in an increased
risk of IS.
To address this, we performed a whole blood transcrip-
tome analysis to identify differences and similarities
between IS-SM versus IS-NSM and C-SM versus C-NSM.
Some of the genes unique to IS-SM may explain why
smokers tend to have poorer outcomes following IS, and
some of the genes common to IS-SM and C-SM may
contribute to the risk of stroke among smokers. To our
knowledge, this study is the first to describe changes of
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gene expression in whole blood at the whole genome level
following ischemic stroke in humans in smokers com-
pared to never smokers.
Methods and materials
Study participants
Subjects (n = 219) were recruited from the Universities of
California at Davis and San Francisco, and the University
of Alberta, Canada. These included 42 IS-current smokers
(IS-SM), 68 IS-never smokers (IS-NSM), 23 control-
smokers (C-SM), and 86 control-never smokers (C-
NSM). Ethics approval was obtained from the institu-
tional review boards, and written informed consent was
obtained from each participant. All procedures followed
institutional guidelines. Diagnosis of IS was made by two
board-certified neurologists based on medical history, and
computed tomographic (CT) and/or magnetic resonance
imaging (MRI) brain scans. Controls include healthy sub-
jects and vascular risk factor subjects. Vascular risk factor
subjects had hypertension, diabetes, and/or hypercholes-
terolemia. Exclusion criteria included prior strokes, active
cancer, infection just before or after strokes, or a rheuma-
tological disorder.
Smoking status was determined by questionnaire. Cur-
rent smokers were those who smoke on average at least
one cigarette per day during the past 12 months. Never
smokers (both stroke S-NS and controls C-NS) had never
smoked by self-report.
Sample processing and total RNA isolation
One venous blood sample was collected from each IS
patient. The time of sample collection ranged from 4.4 to
83.2 h after IS. Blood was drawn into PAX gene tubes
(Qiagen) and stored frozen at 80°C until processed.12,13
Total RNA was extracted according to protocol (PAX-
gene blood RNA kit; Qiagen). RNA quality and concen-
tration were measured using Agilent 2100 Bioanalyzer
and Nano-drop, respectively. A260/A280 absorbance
ratios ≥ 1.8, a 28S/18S rRNA ratio ≥ 1.8, and an RNA
integrity number (RIN) ≥8 were used for determining
RNA quality. Reverse transcription, amplification, and
sample labeling were carried out using Nugen’s Ovation
Whole Blood Solution (Nugen Technologies, San Carlos,
CA) to generate cDNA for analysis on Affymetrix Gen-
eChip arrays.
HTA 2.0 microarray
The Affymetrix HTA 2.0 Gene Chip microarrays (Affyme-
trix, Santa Clara, CA) were used to measure expression of
mRNAs and noncoding RNA. Amplified cDNAs were
hybridized to Affymetrix HTA 2.0 Gene Chip microar-
rays, washed on a Fluidics Station 450 and scanned on a
GeneChip Scanner 3000. Samples were randomly assigned
to microarray batches to reduce batch effect. Microarray
raw gene expression data were saved in CEL files.
Statistical analysis
Raw gene expression data were input into Partek Flow
software (Partek Inc., St. Louis, MO) and normalization
performed using robust multichip averaging (RMA).
Statistical analyses of mRNA data were performed for (1)
IS-SM versus IS-NSM and (2) C-SM versus C-NSM. Uni-
variate analyses were performed to determine confound-
ing factors, including gender, age, race, and vascular risk
factors that might differ between IS-SM and IS-NSM, as
well as C-SM and C-NSM. Fisher’s exact test was used for
categorical variables and unpaired t-test for continuous
variables. A mixed effect regression model was utilized for
differential gene expression analysis, including diagnosis,
smoking status, significant factors from the univariate
analysis, technical variation (batch), gender and interac-
tion between diagnosis and smoking status. The criteria
for determining significantly differentially expressed genes
were P < 0.01 and |fold change| ≥ 1.2. A fold change of
1.2 was used as in our previous studies to help ensure
biologically significant changes and to provide enough
genes for functional pathway analysis.14–17
Functional pathway analyses and cross-
validation analysis
Exploratory Gene Association Networks (EGAN) software
was used to analyze the functional networks. Gene net-
works and pathways were generated according to the
Kyoto Encyclopedia of Genes and Genomes (KEGG) data-
base.
Cross-validation analysis was performed to determine
prediction accuracy of the optimal model using forward
selection and the k-nearest neighbor algorithm in Partek
Genomics Suite 6.4.18 Sensitivity and specificity of the
best classifier were calculated.
Results
Demographic and clinical characteristics
Demographic and clinical characteristics of the 219 sub-
jects are summarized in Table 1. Average age of IS sub-
jects (years  SD) was 60.9  12.6 and 75.5% were male.
There were 55.5% white, 16.4% black, 7.3% Hispanic, 10
% Asian, and 10.9% other race. Hypertension was present
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in 78.2%, diabetes in 41.8%, and hypercholesterolemia in
45.5% of IS subjects. For controls, the average age was
56.7  13.2 and 31.2% were male. For controls 56% were
white, 11% black, 16.5% Hispanic, 8.3% Asian, and 8.3%
other race. 46.8% of controls had hypertension, 11% dia-
betes, and 29.4% hypercholesterolemia. Age, gender, race,
hypertension, diabetes, and hypercholesterolemia were not
significantly different (P > 0.05) in comparisons of IS-SM
versus IS-NSM (Table 2) and C-SM versus C-NSM
(Table 3). In addition, the time-since stroke onset was
not significantly different in the IS-SM versus IS-NSM
groups (Table 2).
Differentially expressed mRNAs, miRNAs,
and lncRNAs
A total of 158 (113 upregulated and 45 downregulated)
genes (RNA) were significantly different between IS-SM
and IS-NSM (P < 0.01, |fold change| ≥ 1.2). Almost a
quarter of the 158 IS-SM versus IS-NSM genes are non-
coding RNA (39 genes), including 3 miRNA, 2 long inter-
genic RNA (LINC), 2 SCARNA, and 32 small nucleolar
RNA (SNORA, SNORD, SNRPN). A total of 100 RNA
(75 up and 25 down) were significantly altered between
C-SM and C-NSM (P < 0.01, |fold change| ≥ 1.2). Of
these 100 RNAs, 21 were noncoding RNAs. Ten genes,
including GPR15, LRRN3, CLDND1, ICOS, GCNT4,
VPS13A, DAP3, HIST1H1D, SNORA54*, and
SCARNA6*, were overexpressed in both the IS-SM versus
IS-NSM and in C-IS versus C-NSM (Fig. 1) (*small non-
coding RNAs).
Functional analysis of regulated mRNAs for
IS-SM versus IS-NSM and C-SM versus C-NSM
Functional pathway analysis showed that the 158 genes
(113 up and 45 down) differentially expressed in blood of
IS-SM versus IS-NSM were over-represented in T-cell
receptor, cytokine–cytokine receptor, chemokine, adipocy-
tokine, tight junction, Jak-STAT, ubiquitin-mediated pro-
teolysis, and adherens junction signaling (Figs. 2 and 3).
The 100 differentially expressed genes (75 up and 25
down) in blood of C-SM versus C-NSM were associated
with cell adhesion, antigen processing and presentation,
T-cell receptor, natural killer cell-medicated cytotoxicity,
cytokine–cytokine receptor interaction, apoptosis, and
endocytosis signaling pathways (Fig. S1).
The mRNA predictive model that was able to best dis-
criminate IS-SM from IS-NSM was generated using a k-
nearest neighbor algorithm (k = 21) with a normalized
correct rate of 79.9% using 27 genes. The sensitivity was
64.3% and specificity was 95.6% for IS-SM.
Discussion
In this study, we identified 158 differentially expressed
genes associated with IS-SM compared to IS-NSM, 100
Table 1. Summary of characteristics of recruited ischemic stroke
patients and control subjects.
Characteristics IS (n = 110)
Control
(n = 109) P-value
Age years (Mean  SD) 60.9  12.6 56.7  13.2 0.02
Gender male n (%） 83 (75.5%) 34 (31.2%) 0.0001
Race Caucasian n (%) 61 (55.5%) 61 (56%) 1
Black 18 (16.4%) 12 (11%) 0.33
Hispanic 8 (7.3%) 18 (16.5%) 0.04
Asian 11 (10%) 9 (8.3%) 0.82
Other race 12 (10.9%) 9 (8.3%) 0.65
Hypertension n (%） 86 (78.2%) 51 (46.8%) 0.0001
Diabetes n (%） 46 (41.8%) 12 (11%) 0.0001
Hypercholesterolemia n (%） 50 (45.5%) 32 (29.4%) 0.0175
Time postevent, hours
(Mean  SD)
43.7 (22.2) N/A N/A
Current Smoker n (%） 42 (38.2%) 23 (21.1%) 0.0076
Never Smoker n (%） 68 (61.8%) 86 (78.9%) 0.0076
Table 2. Demographic variables for smokers with ischemic strokes
(IS-SM) compared to never smokers with ischemic strokes (IS-NSM).
Characteristics
IS-SM
(n = 42)
IS-NSM
(n = 68)
P-
value
Gender male n (%） 33 (78.6%) 50 (73.5%) 0.651
Age years (Mean  SD) 59.6  10.9 61.8  13.5 0.386
Race Caucasian n (%) 25 (59.5%) 36 (52.9%) 0.557
Hypertension n (%） 34 (81%) 52 (76.5%) 0.641
Diabetes n (%） 18 (42.9%) 28 (41.2%) 1
Hypercholesterolemia n (%） 17 (40.5%) 33 (48.5%) 0.437
Time postevent, hours
(Mean  SD)
42  23.2 44.8  21.7 0.526
P-values represent the comparisons of IS-SM versus IS-NSM using t-
test, Chi-square, or Fisher’s exact test where appropriate.
Table 3. Demographic variables for control-smokers (C-SM) com-
pared to control-never smokers (C-NSM).
Characteristics
C-SM
(n = 23)
C-NSM
(n = 86)
P-
value
Gender male n (%） 10 (43.5%) 24 (27.9%) 0.205
Age years (Mean  SD) 58.7  9 56.2  14.1 0.423
Race Caucasian n (%) 14 (60.9%) 47 (54.7%) 0.643
Hypertension n (%） 7 (30.4%) 44 (51.2%) 0.101
Diabetes n (%） 3 (13%) 9 (10.5%) 0.714
Hypercholesterolemia n (%） 3 (13%) 29 (33.7%) 0.071
Time postevent, hours
(Mean  SD)
N/A N/A N/A
P-values represent the comparisons of C-SM versus C-NSM using t-
test, Chi-square, or Fisher’s exact test where appropriate.
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altered genes associated with C-SM compared to C-NSM,
and 10 common genes for IS-SM versus IS-NSM and C-
SM versus C-NSM. Some of the 10 common genes
(GPR15, LRRN3, CLDND1, ICOS, GCNT4, VPS13A,
DAP3, HIST1H1D, SNORA54, and SCARNA6) could be
associated with stroke risk since they are expressed in
smokers before stroke and in smokers after stroke. For
example, regulation of ICOS affects outcomes in experi-
mental rodent stroke models by modulating T cells.19
Chorea-acanthocytosis (ChAc), a neurodegenerative dis-
ease, results from loss-of-function mutations of the chor-
ein-encoding gene VPS13A.20 Perhaps smoking induced
Figure 1. Differentially expressed genes (P-value < 0.01; |fold change| ≥ 1.2) in ischemic stroke-smokers (IS-SM) versus ischemic stroke-never
smokers (IS-NSM), and in control-smokers (C-SM) versus control-never smokers (C-NSM). Abbreviations: GPR15, G Protein-Coupled Receptor 15;
LRRN3, Leucine Rich Repeat Neuronal 3; CLDND1, Claudin Domain Containing 1; ICOS, Inducible T-Cell Costimulator; GCNT4, Glucosaminyl (N-
Acetyl) Transferase 4; VPS13A, Vacuolar Protein Sorting 13 Homolog A; DAP3, Death-Associated Protein 3; SNORA54, Small Nucleolar RNA, H/
ACA Box 54; HIST1H1D, Histone Cluster 1 H1 Family Member D; SCARNA6, Small Cajal Body-Specific RNA 6.
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Figure 2. Top inflammatory response and immune response-related functional pathways for regulated genes associated with IS-SM when
compared to IS-NSM. Abbreviations: TRAT1, T-Cell Receptor Associated Transmembrane Adaptor 1; ICOS, Inducible T-Cell Costimulator; CD3E,
CD3e Molecule; ITK, IL2 Inducible T-Cell Kinase; KCNA3, Potassium Voltage-Gated Channel Subfamily A Member 3; PRKCQ, Protein Kinase C
Theta; CASK, Calcium/Calmodulin-Dependent Serine Protein Kinase; AKT3, AKT Serine/Threonine Kinase 3; IL7R, Interleukin 7 Receptor; CCR4, C-
C Motif Chemokine Receptor 4; CCR8, C-C Motif Chemokine Receptor 8; GRK4, G Protein-Coupled Receptor Kinase 4.
Figure 3. Significant metabolic pathways, Ubiquitin-mediated proteolysis pathway and Adherens junction and Wnt signaling pathway for
regulated genes associated with IS-SM when compared to IS-NSM. Abbreviations: LEF1, Lymphoid Enhancer-Binding Factor 1; TCF7, Transcription
Factor 7; BRCA1, BRCA1, DNA Repair Associated; TERF2, Telomeric Repeat-Binding Factor 2; CCNC, Cyclin C; MID1, Midline 1; AOC2, Amine
Oxidase, Copper Containing 2; C1GALT1C1, C1GALT1 Specific Chaperone 1; DAO, D-Amino Acid Oxidase; GLS, Glutaminase; SLC33A1, Solute
Carrier Family 33 Member 1; GCNT4, Glucosaminyl (N-Acetyl) Transferase 4; ADSL, Adenylosuccinate Lyase.
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changes in levels of VPS13A would affect red blood cells
and predispose to clotting/stroke. HIST1H1D and DAP3
are involved in apoptosis, and SNORA54 is associated
with Factor X which plays a key role in clotting (Gene-
Cards). GPR15, LRRN3, and CLDND1 are discussed next.
A previous transcriptome meta-analysis reported the top
25 smoking-related genes associated with current smokers
versus never smokers.21 Comparing our 100 smoking genes
identified in C-SM versus C-NSM with the top 25 smok-
ing-related genes identified in this previous meta-analysis
(n = 25), we found three genes (GPR15, LRRN3, and
CLDND1) overlapped, which is highly significant based on
a hypergeometric probability test (P < 0.0002). These three
genes were also among the 10 common genes differentially
expressed in IS-SM, as well as in C-SM (Fig. 1, overlap).
Notably, smoking is the only condition known to increase
the numbers of GPR15+ T cells in blood22 which are pro-
inflammatory Th17-like.23 GPR15 is an orphan receptor
that is involved in the regulation of the innate immunity
and T-cell trafficking.24 GPR15 and LRRN3 have DNA
methylation loci in their promoter regions that are reported
to be hypomethylated among smokers which might indi-
cate smoking-induced epigenetic changes.21 LRRN3 is an
inflammatory regulatory gene related to T-cell function
and immunosenescence whose expression declines with
age25 and smoking, perhaps resulting in a dysregulated
immune system prior to and after stroke. Claudin domain-
containing 1 (CLDND1), also known as claudin-25, plays a
role in the development of cerebrovascular disease in
stroke-prone spontaneously hypertensive rats.26 Perhaps
smoking induction of CLDND1 is a risk factor for stroke in
humans as well.
Some of the 158 genes expressed after stroke in smok-
ers could be associated with the worse stroke outcomes in
smokers. It is notable that most of the genes associated
with IS-SM versus IS-NSM compared to C-SM versus C-
NSM were different/unique for each. This suggests that
smoking has a strong interaction with stroke associated
responses in peripheral leukocytes and platelets that is
quite different from control-smokers compared to con-
trol-never smokers.
Of the 158 differentially expressed genes associated with
IS-SM many were in pro-inflammatory pathways including
T-cell receptor signaling (CD3E, TRAT1, ICOS, ITK,
AKT3, PRKCQ, KCNA3), chemokine signaling (GRK4,
CCR4, CCR8, AKT3 ITK, GPR15), cytokine–cytokine
receptor interaction (IL7R, CCR4, CCR8), adipocytokine
signaling (AKT3, PRKCQ, KCNA3), hypertension (GRK4),
and tight junction pathways (CASK, AKT3). These path-
ways which are activated in peripheral blood leukocytes,
platelets, and other blood cells could promote more clotting
and oxidative stress and contribute to smoking-induced
injury in brain and worse stroke outcomes in smokers.
Many of the IS-SM genes were associates either with T
lymphocytes or T-cell receptor (TCR) signaling including
CD3E, ICOS, PRKCQ, LEF1, TCF7, and IL7R. T cells
increase inflammation in atherosclerotic plaques and con-
tribute to lesion development, and T cells infiltrate
ischemic brain and may be beneficial or harmful.27,28 For
example, an anti-CD3 antibody reduced atherosclerotic
plaque development in mice.29 Patients with myocardial
infarction (MI) and/or stable angina who were diagnosed
with atherosclerosis had associated decreases of ICOS+ T
cell subset and Treg cells, suggesting a possible role for
these cells.30 A protective role of ICOS was observed in
ApoE-KO mouse model.31 Protein Kinase C Theta
(PRKCQ) is a serine/threonine protein kinase expressed in
T lymphocytes and modulates proliferation and cytokine
production and is required for T-cell driven inflammatory
responses.32,33 PRKCQ is also highly expressed in platelets
and positively regulates thrombin-mediated platelet activa-
tion and aggregation.34 Interleukin receptor IL7R was
upregulated in the peripheral blood of IS-SM. IL7 regulates
T-cell differentiation, survival, and homeostasis, which
mediates inflammation upon binding to IL7R.35 Increased
gene expression of IL7R and lnc-IL7R are observed in many
inflammatory conditions including atherosclerotic plaques
in humans.36–39 Thus, the dysregulation of some of the
above T-cell receptor signaling pathways could contribute
to worsened ischemic brain injury in smokers.
CCR4 and CCR8 are also upregulated in IS-SM. These
are CC chemokine receptors that mediate leukocytes
chemotaxis and play regulatory roles in the inflammatory
response upon interaction with their chemokines.
Atherosclerosis is associated with the recruitment of
monocytes and T lymphocytes to the vascular wall of
blood vessels. The dendritic cell-derived chemokine
CCL17 is a ligand for CCR4. An atherosclerosis-prone
mice study showed that CCL17 deficiency resulted in a
reduction of atherosclerosis, which was dependent on
Tregs.40,41 Another study found that CCR4 expression
was decreased by simvastatin accompanied by anti-in-
flammation and lipid-lowering effects in human endothe-
lial cells and macrophages.42 These findings suggested
CCR4 is involved in promoting atherosclerosis. In addi-
tion to the role in atherosclerosis, studies have shown that
CCR4 was expressed on platelets and triggered platelet
activation and aggregation via binding to its ligands
including macrophage-derived chemokine in Th2 diseases
such as asthma and atopic dermatitis.43,44
CCR8 is found on monocytes, T lymphocytes, endothe-
lial cells, and vascular smooth muscle cells in human.45–47
These cells produce CCR8 ligand, CCL1/I-309, mediating
the effects of Lipoprotein(a) in atherosclerosis. CCR8 was
also identified on endothelium of human atherosclerotic
plaques and induced angiogenesis when interacting with
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CCL1.45,48 These data showed that CCR8, an endothelial
receptor, may regulate endothelial function and partici-
pate in arterial vessel wall pathology. In the current study,
both CCR4 and CCR8 are upregulated in IS current smo-
ker patients, which may suggest a role of current smoking
in increasing stroke injury by promoting atherosclerosis
and platelet aggregation.
Smoking also activates the Wnt signaling pathway via
LEF1 and TCF7 which modulate adherens junctions.
LEF1 is a transcriptional repressor which activates HDACs
which downregulate expression of many genes important
in the pathogenesis of stroke.49 Indeed, HDAC inhibitors
in humans can decrease the risk of stroke after a previous
stroke or TIA.50 Thus, smoking activation of LEF1 would
be expected to activate HDACs which could worsen
stroke outcomes.
There were many noncoding RNAs (ncRNA) that were
associated with stroke in smokers (IS-SM). Many of the
ncRNA, including microRNA and long noncoding RNA, can
regulate mRNA expression. As an example, SNORA54
appears to modify expression of Factor X and thus could play
a role in clotting related to smoking-associated strokes (Gen-
eCards). Another example is SCARNA6, a small Cajal body-
specific RNA which are in a class of small nucleolar RNAs
(snoRNAs) that localize to the Cajal body, a nuclear organelle
involved in the biogenesis of small nuclear ribonucleopro-
teins (snRNPs or snurps). ScaRNAs guide methylation and
pseudouridylation of RNA polymerase II transcribed spliceo-
somal RNAs U1, U2, U4, U5, and U12 to modulate splicing
which might be another impact of smoking in stroke.51
One limitation is small sample size. Future larger stud-
ies will be required to validate the findings in a separate
cohort. Another limitation is the inability to prove causal
relationship between smoking, gene expression and clini-
cal outcomes in IS patients due to this being cross-sec-
tional study. While the gene profiling provides evidence
for hypothesis generation, in vitro and in vivo functional
experiments need to be performed to establish causality
that the identified genes represent either stroke risk genes
or represent genes that contribute to smoking-induced
worsening of stroke.
Conclusions
These studies provide a novel list of targets to possibly
decrease stroke risk or improve stroke outcomes in smokers.
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